Literature DB >> 28492994

Metabolic characteristics and renal dysfunction in 65 patients with tophi prior to gout.

Chuan-Chin Lu1,2, Shyi-Kuen Wu2, Wei-Sheng Chung3,4, Liang-Hung Lin1, Ta-Wei Hung1, Chih-Jung Yeh5,6.   

Abstract

Tophi typically occur many years after uncontrolled gout. Therefore, their development before gout remains unusual. Such patients might exhibit some characteristic differences compared with typical tophaceous gout patients. In this study, 65 tophaceous gout patients with tophi as the first sign of gout (tophi-first group) were enrolled. Their clinical characteristics were compared with those of 1421 patients whose tophi occurred after gout (tophi-after group). Compared with the tophi-after group, the tophi-first group had a significantly higher percentage of female patients and patients with elderly onset of disease and a lower percentage of patients with a positive family history; these patients had lower body mass indices, serum urate levels, and estimated glomerular filtration rates (eGFRs). Female sex and negative family history were identified as the principal determinants of tophi development before gout. The decreasing eGFR among the tophi-first group was not due to the group per se but was a result of older age, longer tophi duration, and hyperuricemia. The most common site of initial tophi occurrence in both groups was the toe. In the tophi-first group, the occurrence rates for initial tophi sites were significantly higher at the finger but were lower at the ankle. The tophi-first group exhibited distinct characteristics of age, gender, family history, BMI, serum urate levels, and initial tophi site. This group had fewer comorbidities but similar renal dysfunction compared with the tophi-after group. Thus, patients presenting with tophi should be treated promptly, even if they have no history of gout symptoms.

Entities:  

Keywords:  Comorbidity; Female; Gout; Renal dysfunction; Tophi

Mesh:

Substances:

Year:  2017        PMID: 28492994     DOI: 10.1007/s10067-017-3663-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  35 in total

Review 1.  Global epidemiology of gout: prevalence, incidence and risk factors.

Authors:  Chang-Fu Kuo; Matthew J Grainge; Weiya Zhang; Michael Doherty
Journal:  Nat Rev Rheumatol       Date:  2015-07-07       Impact factor: 20.543

2.  NLRP3 inflammasome activation is required for fibrosis development in NAFLD.

Authors:  Alexander Wree; Matthew D McGeough; Carla A Peña; Martin Schlattjan; Hongying Li; Maria Eugenia Inzaugarat; Karen Messer; Ali Canbay; Hal M Hoffman; Ariel E Feldstein
Journal:  J Mol Med (Berl)       Date:  2014-05-28       Impact factor: 4.599

3.  Dermal tophus: a complication of gout in a kidney transplant recipient.

Authors:  Ebru Hatice Ayvazoglu Soy; Emre Karakaya; Arzu Karatas Togral; Aydincan Akdur; Gokhan Moray; Mehmet Haberal
Journal:  Exp Clin Transplant       Date:  2015-04       Impact factor: 0.945

4.  Intraosseous Gouty Tophus in the Talus: A Case Report.

Authors:  Chin-Horng Su; Jui-Kuo Hung
Journal:  J Foot Ankle Surg       Date:  2014-10-18       Impact factor: 1.286

5.  Intraosseous tophus deposits in the os trigonum.

Authors:  Ersin Ercin; Mehmet Gamsizkan; Serdar Avsar
Journal:  Orthopedics       Date:  2012-01-16       Impact factor: 1.390

6.  A Role for Gut Microbiota and the Metabolite-Sensing Receptor GPR43 in a Murine Model of Gout.

Authors:  Angélica T Vieira; Laurence Macia; Izabela Galvão; Flaviano S Martins; Maria Cecília C Canesso; Flávio A Amaral; Cristiana C Garcia; Kendle M Maslowski; Ellen De Leon; Doris Shim; Jacques R Nicoli; Jacquie L Harper; Mauro M Teixeira; Charles R Mackay
Journal:  Arthritis Rheumatol       Date:  2015-06       Impact factor: 10.995

7.  Associations between gout tophus and polymorphisms 869T/C and -509C/T in transforming growth factor beta1 gene.

Authors:  S-J Chang; C-J Chen; F-C Tsai; H-M Lai; P-C Tsai; M-H Tsai; Y-C Ko
Journal:  Rheumatology (Oxford)       Date:  2008-03-19       Impact factor: 7.580

Review 8.  Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications.

Authors:  Elisa Fabbrini; Shelby Sullivan; Samuel Klein
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

9.  The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance.

Authors:  Bolormaa Vandanmagsar; Yun-Hee Youm; Anthony Ravussin; Jose E Galgani; Krisztian Stadler; Randall L Mynatt; Eric Ravussin; Jacqueline M Stephens; Vishwa Deep Dixit
Journal:  Nat Med       Date:  2011-01-09       Impact factor: 53.440

10.  2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Authors:  Tuhina Neogi; Tim L Th A Jansen; Nicola Dalbeth; Jaap Fransen; H Ralph Schumacher; Dianne Berendsen; Melanie Brown; Hyon Choi; N Lawrence Edwards; Hein J E M Janssens; Frédéric Lioté; Raymond P Naden; George Nuki; Alexis Ogdie; Fernando Perez-Ruiz; Kenneth Saag; Jasvinder A Singh; John S Sundy; Anne-Kathrin Tausche; Janitzia Vaquez-Mellado; Steven A Yarows; William J Taylor
Journal:  Ann Rheum Dis       Date:  2015-10       Impact factor: 19.103

View more
  2 in total

Review 1.  Asymptomatic hyperuricemia: is it time to intervene?

Authors:  Binoy J Paul; K Anoopkumar; Vinod Krishnan
Journal:  Clin Rheumatol       Date:  2017-10-04       Impact factor: 2.980

2.  Analysis of Risk Factors for Changes in the Renal Two-Dimensional Image in Gout Patients.

Authors:  Wantai Dang; Xiaohui Xu; Danling Luo; Hui Luo; Jin Hu; Jingguo Zhou; Jian Liu; Lanlan You
Journal:  Int J Gen Med       Date:  2021-10-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.